Robert Blum

Chief Executive Officer, President & Director, Cytokinetics

Search every verified Robert Blum interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Robert Blum, CEO of Cytokinetics, discussed the company's trajectory and strategy in a February 2025 podcast appearance. He noted that Cytokinetics, which he joined in 1998 and has led as CEO since 2007, has operated for over 25 years without a marketed product in the U.S., having invested more than $2.5 billion. Blum stated that the company expects FDA clearance this year for its first product, aficamten, a cardiac myosin inhibitor for hypertrophic cardiomyopathy, which has shown improved exercise capacity and clinical outcomes in trials. He described the company's long-term goal as building a fully integrated commercial biopharmaceutical enterprise focused on muscle disorders, drawing on lessons from his earlier career at Marion Laboratories and Core Therapeutics. Blum also commented on the competitive landscape, saying that Bristol Myers Squibb's mavacamten, a similar drug for the same condition, is performing well and could exceed $1 billion in annual sales, but he estimated its market penetration remains low at 10–15%. He expressed a belief that continued innovation, including with aficamten, benefits all stakeholders, and he outlined aspirations for Cytokinetics to be counted among major biopharma companies like Vertex, Amgen, Regeneron, and Gilead in the coming five to ten years.